vs
Esperion Therapeutics, Inc.（ESPR）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是REPUBLIC BANCORP INC的1.8倍（$168.4M vs $94.3M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 5.3%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -11.5%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
ESPR vs RBCAA — 直观对比
营收规模更大
ESPR
是对方的1.8倍
$94.3M
营收增速更快
ESPR
高出138.4%
5.3%
两年增速更快
ESPR
近两年复合增速
-11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $94.3M |
| 净利润 | — | $22.8M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 29.3% |
| 净利率 | — | 24.2% |
| 营收同比 | 143.7% | 5.3% |
| 净利润同比 | — | 20.0% |
| 每股收益（稀释后） | $0.32 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRRBCAA
| Q4 25 | $168.4M | $94.3M | ||
| Q3 25 | $87.3M | $93.5M | ||
| Q2 25 | $82.4M | $93.8M | ||
| Q1 25 | $65.0M | $135.8M | ||
| Q4 24 | $69.1M | $89.5M | ||
| Q3 24 | $51.6M | $88.1M | ||
| Q2 24 | $73.8M | $86.9M | ||
| Q1 24 | $137.7M | $120.3M |
净利润ESPRRBCAA
| Q4 25 | — | $22.8M | ||
| Q3 25 | $-31.3M | $29.7M | ||
| Q2 25 | $-12.7M | $31.5M | ||
| Q1 25 | $-40.5M | $47.3M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | $-29.5M | $26.5M | ||
| Q2 24 | $-61.9M | $25.2M | ||
| Q1 24 | $61.0M | $30.6M |
营业利润率ESPRRBCAA
| Q4 25 | 50.6% | 29.3% | ||
| Q3 25 | -11.4% | 40.4% | ||
| Q2 25 | 8.6% | 43.0% | ||
| Q1 25 | -34.0% | 44.1% | ||
| Q4 24 | -6.4% | 25.8% | ||
| Q3 24 | -31.0% | 38.4% | ||
| Q2 24 | 3.5% | 37.0% | ||
| Q1 24 | 52.5% | 32.2% |
净利率ESPRRBCAA
| Q4 25 | — | 24.2% | ||
| Q3 25 | -35.9% | 31.8% | ||
| Q2 25 | -15.4% | 33.5% | ||
| Q1 25 | -62.2% | 34.8% | ||
| Q4 24 | — | 21.2% | ||
| Q3 24 | -57.2% | 30.1% | ||
| Q2 24 | -83.9% | 29.0% | ||
| Q1 24 | 44.3% | 25.4% |
每股收益（稀释后）ESPRRBCAA
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.34 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $220.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $1.1B |
| 总资产 | $465.9M | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRRBCAA
| Q4 25 | $167.9M | $220.0M | ||
| Q3 25 | $92.4M | $484.2M | ||
| Q2 25 | $86.1M | $484.8M | ||
| Q1 25 | $114.6M | $793.0M | ||
| Q4 24 | $144.8M | $432.2M | ||
| Q3 24 | $144.7M | $530.9M | ||
| Q2 24 | $189.3M | $400.1M | ||
| Q1 24 | $226.6M | $546.4M |
股东权益ESPRRBCAA
| Q4 25 | $-302.0M | $1.1B | ||
| Q3 25 | $-451.4M | $1.1B | ||
| Q2 25 | $-433.5M | $1.1B | ||
| Q1 25 | $-426.2M | $1.0B | ||
| Q4 24 | $-388.7M | $992.0M | ||
| Q3 24 | $-370.2M | $979.7M | ||
| Q2 24 | $-344.2M | $955.4M | ||
| Q1 24 | $-294.3M | $935.6M |
总资产ESPRRBCAA
| Q4 25 | $465.9M | $7.0B | ||
| Q3 25 | $364.0M | $7.0B | ||
| Q2 25 | $347.1M | $7.0B | ||
| Q1 25 | $324.0M | $7.1B | ||
| Q4 24 | $343.8M | $6.8B | ||
| Q3 24 | $314.1M | $6.7B | ||
| Q2 24 | $352.3M | $6.6B | ||
| Q1 24 | $373.1M | $6.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | — | $161.1M |
| 自由现金流率自由现金流/营收 | — | 170.9% |
| 资本支出强度资本支出/营收 | 0.0% | 7.5% |
| 现金转化率经营现金流/净利润 | — | 7.37× |
| 过去12个月自由现金流最近4个季度 | — | $288.6M |
8季度趋势，按日历期对齐
经营现金流ESPRRBCAA
| Q4 25 | $45.2M | $168.2M | ||
| Q3 25 | $-4.3M | $33.3M | ||
| Q2 25 | $-31.4M | $8.4M | ||
| Q1 25 | $-22.6M | $93.2M | ||
| Q4 24 | $-35.0M | $149.0M | ||
| Q3 24 | $-35.3M | $51.3M | ||
| Q2 24 | $-7.2M | $4.0M | ||
| Q1 24 | $53.8M | $71.2M |
自由现金流ESPRRBCAA
| Q4 25 | — | $161.1M | ||
| Q3 25 | — | $30.8M | ||
| Q2 25 | — | $5.2M | ||
| Q1 25 | — | $91.6M | ||
| Q4 24 | — | $143.2M | ||
| Q3 24 | $-35.5M | $49.8M | ||
| Q2 24 | $-7.3M | $2.7M | ||
| Q1 24 | $53.8M | $69.1M |
自由现金流率ESPRRBCAA
| Q4 25 | — | 170.9% | ||
| Q3 25 | — | 32.9% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | 67.4% | ||
| Q4 24 | — | 160.0% | ||
| Q3 24 | -68.7% | 56.5% | ||
| Q2 24 | -9.9% | 3.1% | ||
| Q1 24 | 39.0% | 57.5% |
资本支出强度ESPRRBCAA
| Q4 25 | 0.0% | 7.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 6.5% | ||
| Q3 24 | 0.3% | 1.7% | ||
| Q2 24 | 0.1% | 1.5% | ||
| Q1 24 | 0.1% | 1.7% |
现金转化率ESPRRBCAA
| Q4 25 | — | 7.37× | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 1.97× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 1.93× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | 0.88× | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
RBCAA
暂无分部数据
